Gamida Cell Revenue and Competitors
Estimated Revenue & Valuation
- Gamida Cell's estimated annual revenue is currently $20.8M per year.
- Gamida Cell's estimated revenue per employee is $155,000
- Gamida Cell's total funding is $267.8M.
Employee Data
- Gamida Cell has 134 Employees.
- Gamida Cell grew their employee count by 10% last year.
Gamida Cell Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $15.3M | 99 | -49% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $9.6M | 62 | -7% | N/A | N/A |
#10 | $14.7M | 95 | 12% | N/A | N/A |
What Is Gamida Cell?
Gamida Cell is a leader in cellular and immune therapeutics, committed to changing the treatment paradigm for patients with cancer and rare genetic diseases. We are building a broad pipeline based on our proprietary NAM technology platform. Our lead program, NiCord, is in phase 3 development for allogeneic bone marrow transplantation and was granted Breakthrough Therapy Designation by the FDA.
keywords:N/A
$267.8M
Total Funding
134
Number of Employees
$20.8M
Revenue (est)
10%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Gamida Cell News
GDA-201 is an off-the-shelf cell therapy candidate for the treatment of patients with follicular and diffuse large B cell lymphomas, Gamida...
Gamida Cell Presents Updated One-Year Post-Transplant Follow Up Data from Phase 3 Study of Omidubicel at 2022 Transplantation & Cellular Therapy...
Paul Schloesser. Associate Editor. The small Boston-based cell therapy outfit Gamida Cell recently axed 10% of its workforce in order to...
Gamida Cell to Present NAM-Enabled, Genetically Modified NK Cell Therapy Pipeline and Update on GDA-201 at Today's Virtual R&D Day ● Company recently filed an IND application for GDA-201; FDA placed the application on Clinical Hold pending modifications to donor eligibility procedures and ster ...
Every investor in Gamida Cell Ltd. (NASDAQ:GMDA) should be aware of the most powerful shareholder groups. Insiders often own a large ...
Other Companies in Jerusalem
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | N/A | 149 | 18% | N/A |
#2 | $44.2M | 176 | 9% | N/A |
#3 | $29.4M | 191 | 26% | N/A |
#4 | $7.5M | 196 | 15% | $140.2M |
#5 | N/A | 240 | 17% | N/A |